While true, there is more money going in executive compensation / stock than into research.
So there is plenty of space for lower prices. Plenty.
So there is plenty of space for lower prices. Plenty.
Here's the 2023 report from Roche, which owns Genentech.
https://assets.roche.com/f/176343/x/0ef2047502/ar23-roche-ho...
Page 17 shows that R&D costs for pharma is 10-20x larger than equity-based compensation. That's all stock-based compensation, for execs and regular people. Your claim is that it's the opposite.
Take Pfizer, R&D is $11B. You think executive comp is more than $11B?
The CEO total comp is $24M or 2%. The exec team is less than 10 people.
At least try to make believable claims.